Understanding how T cells target tumors in lung cancer
Official title: The antigen specificity of tumor-targeting T cells in non-small cell lung cancer
Funded at Yale University · NIH-11085090 · Data updated 2026-11-12
This study is looking at how to make your immune cells, called T cells, better at fighting non-small cell lung cancer by customizing them to target your specific tumors, and it may involve you giving a blood sample to help find the best treatment for you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $277,857 |
| NIH project number | 5K08CA270191-03 |
| Project ID | NIH-11085090 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of lung cancer or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research investigates the specific ways in which T cells, a type of immune cell, can be directed to attack tumors in patients with non-small cell lung cancer. The project focuses on enhancing adoptive cell therapy, which involves modifying T cells to improve their ability to recognize and destroy cancer cells. Patients may be involved in providing blood samples to help identify the most effective T cell responses against their tumors. The research aims to develop personalized treatment strategies that could lead to better outcomes for lung cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized immunotherapies for patients with non-small cell lung cancer.
How similar studies have gone: Previous research has shown promising results in using T cell therapies for various cancers, indicating that this approach has potential for success.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Lee, Mark N. — Yale University
- Study coordinator: Lee, Mark N.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.